Billionaire Profile
Zhao Tao
Global Rank
#2044

Image: Soboky | CC BY-SA 4.0 | via Wikimedia Commons

Zhao Tao

CEO, Pharmaceuticals
SINGAPORE
Real-Time Net Worth
$1.99B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
+1.91% (24h)
Age
49
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
SINGAPORE

Biography

Zhao Tao is a prominent figure in the pharmaceutical industry, currently serving as the chairman of Shandong Buchang Pharmaceuticals. Born in China, Zhao holds a Singapore passport and earned an MBA from Fordham University in New York City. Her career has been marked by significant achievements, including leading Shandong Buchang Pharmaceuticals, a major supplier of traditional Chinese medicine for cardiovascular diseases. Her involvement in a Stanford bribery scandal brought her further into the public eye, but she has continued her leadership role in the pharmaceutical sector. Zhao is also known for her past connection to acupuncture, which gained her recognition in Singapore in the 1990s. The recent Forbes list estimated her net worth to be US$1.8 billion.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Zhao Tao was born in China on January 28, 1977. In the 1990s, before becoming a billionaire, Zhao gained recognition in Singapore for her acupuncture skills. She was involved in the field of Traditional Chinese Medicine (TCM). At the time, she was a visiting TCM doctor from China, and her father, Zhao Buchang, was a prestigious doctor. She attended an international conference on TCM and Acupuncture in Singapore in 1992.

Rise to Success

Zhao's father, Zhao Buchang, started Shandong Buchang Pharmaceuticals. Zhao holds a Singapore passport. He received an MBA from Fordham University. Buchang started trading on the Shanghai Stock Exchange in November 2016. Zhao Tao is the chairman of Shandong Buchang Pharmaceuticals, a supplier of traditional Chinese medicine to fight cardiovascular disease.

Key Business Strategies

Under Zhao Tao's leadership, Shandong Buchang Pharmaceuticals has focused on the production and distribution of traditional Chinese medicine. In 2018, Buchang Pharmaceuticals earned RMB80 billion (S$16.1 billion). The company was also the first pharmaceutical company to invest in advertisements. The company's emphasis on advertising and marketing was exceptionally heavy. In fact, its marketing spending superseded the spending on research and development.

Philanthropy

Specific philanthropic endeavors of Zhao Tao are not readily available in the search results. However, she is a vice president of the China Overseas Chinese Entrepreneurs Association and the chief supervisor of the Shandong Overseas Chinese Entrepreneurs Association.

Career Milestones

2001

Chairman of Shandong Buchang Pharmaceuticals

Assumed the role of chairman, leading the company's operations and strategic direction.

2016

Buchang Pharmaceuticals IPO

Led the company through its initial public offering on the Shanghai Stock Exchange.

Philanthropy & Social Impact

Community Service

China Overseas Chinese Entrepreneurs Association

Undisclosed

Serves as the Vice President of this association.

Community Service

Shandong Overseas Chinese Entrepreneurs Association

Undisclosed

Serves as the chief supervisor of this association.

Controversies & Challenges

2007

Bribery Scandal

Buchang Pharmaceuticals was involved in bribing the head of China's State Food & Drug Administration.

2019

Stanford Admissions Scandal

Accused of paying millions to get his daughter into Stanford University.